The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). From this collection, the NHCS contributes data that may inform emerging national health threats such as the current opioid public health emergency. The 2022 - 2024 NHCS are not yet fully operational so it is important to note that the data presented here are preliminary and not nationally representative. The data are from 24 hospitals submitting inpatient and 23 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from October 1, 2022–September 30, 2024. Even though the data are not nationally representative, they can provide insight into the use of opioids and other overdose drugs. The NHCS data is submitted from various types of hospitals (e.g., general/acute, children’s, etc.) and can show results from a variety of indicators related to drug use, such as overall drug use, comorbidities, and drug and polydrug overdose. NHCS data can also be used to report on patient conditions within the hospital over time.

For those interested in data on student drug addiction in 2024, several sources offer valuable datasets and statistics.

1. Kaggle Dataset: Kaggle hosts a specific dataset on student drug addiction. This dataset includes various attributes related to student demographics, substance use patterns, and associated behavioral factors. It's a useful resource for data analysis and machine learning projects focused on understanding drug addiction among students【5†source】.

2. National Survey on Drug Use and Health (NSDUH): This comprehensive survey provides detailed annual data on substance use and mental health across the United States, including among students. It covers a wide range of substances and demographic details, helping to track trends and the need for treatment services【6†source】【8†source】.

3. Monitoring the Future (MTF) Survey: Conducted by the National Institute on Drug Abuse (NIDA), this survey tracks drug and alcohol use and attitudes among American adolescents. It provides annual updates and is an excellent source for understanding trends in substance use among high school and college students【7†source】.

4. Australian Institute of Health and Welfare (AIHW): For those interested in a more global perspective, the AIHW offers data from the National Drug Strategy Household Survey, which includes information on youth and young adult drug use in Australia. This can be useful for comparative studies【10†source】.

For detailed datasets and further analysis, you can explore these resources directly:

• Kaggle Student Drugs Addiction Dataset
• NSDUH Data
• Monitoring the Future
• AIHW Drug Survey

The National Survey on Drug Use and Health (NSDUH) provides national and state-level data on the use of tobacco, alcohol, illicit drugs (including non-medical use of prescription drugs) and mental health in the United States. This annual survey involves interviews with approximately 70,000 randomly selected individuals aged 12 and older. NSDUH is sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency of the U.S. Public Health Service in the U.S. Department of Health and Human Services (DHHS).

The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2015 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.

The National Household Survey on Drug Abuse (NHSDA) series
measures the prevalence and correlates of drug use in the United
States. The surveys are designed to provide quarterly, as well as
annual, estimates. Information is provided on the use of illicit
drugs, alcohol, and tobacco among members of United States households
aged 12 and older. Questions include age at first use as well as
lifetime, annual, and past-month usage for the following drug classes:
marijuana, cocaine (and crack), hallucinogens, heroin, inhalants,
alcohol, tobacco, and nonmedical use of prescription drugs, including
pain relievers, tranquilizers, stimulants, and sedatives. The survey
covers substance abuse treatment history and perceived need for
treatment, and includes questions from the Diagnostic and Statistical
Manual (DSM) of Mental Disorders that allow diagnostic criteria to be
applied. Respondents are also asked about personal and family income
sources and amounts, health care access and coverage, illegal
activities and arrest record, problems resulting from the use of
drugs, and needle-sharing. Questions introduced in previous NHSDA
administrations were retained in the 1999 survey, including questions
asked only of respondents aged 12 to 17. These "youth experiences"
items covered a variety of topics, such as neighborhood environment,
illegal activities, gang involvement, drug use by friends, social
support, extracurricular activities, exposure to substance abuse
prevention and education programs, and perceived adult attitudes
toward drug use and activities such as school work. Also retained were
questions on mental health and access to care, perceived risk of using
drugs, perceived availability of drugs, driving behavior and personal
behavior, and cigar smoking. Questions on the tobacco brand used most
often were introduced with the 1999 survey. Demographic data include
gender, race, age, ethnicity, marital status, educational level, job
status, veteran status, and current household composition.This study has 1 Data Set.

Drug Use By Age

This directory contains data behind the story How Baby Boomers Get High. It covers 13 drugs across 17 age groups.

Source: National Survey on Drug Use and Health from the Substance Abuse and Mental Health Data Archive.

Heroin Use reports an estimated average percent of people who consumed heroin, by age range. These data are collected by the Substance Abuse and Mental Health Services Administration (SAMHSA) as part of the National Survey on Drug Use and Health (NSDUH), Substate Region Estimates by Age Group. This survey is conducted on a representative sample of U.S. civilian, non-institutionalized people ages 12 and older. Data are available for the state of Connecticut, substate regions within Connecticut, the Northeast region of the United States, and the Total United States.

The Drug Abuse Warning Network (DAWN) survey is designed to
capture data on emergency department (ED) episodes that are induced by
or related to the use of an illicit, prescription, or over-the-counter
drug. For purposes of this collection, a drug "episode" is an ED visit
that was induced by or related to the use of an illegal drug or the
nonmedical use of a legal drug for patients aged six years and
older. A drug "mention" refers to a substance that was mentioned
during a drug-related ED episode. Because up to four drugs can be
reported for each drug abuse episode, there are more mentions than
episodes in the data. Individual persons may also be included more
than once in the data. Within each facility participating in DAWN, a
designated reporter, usually a member of the emergency department or
medical records staff, was responsible for identifying drug-related
episodes and recording and submitting data on each case. An episode
report was submitted for each patient visiting a DAWN emergency
department whose presenting problem(s) was/were related to their own
drug use. DAWN produces estimates of drug-related emergency department
visits for 50 specific drugs, drug categories, or combinations of
drugs, including the following: acetaminophen, alcohol in combination
with other drugs, alprazolam, amitriptyline, amphetamines, aspirin,
cocaine, codeine, diazepam, diphenhydramine, fluoxetine,
heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam,
marijuana/hashish, methadone, methamphetamine, and PCP/PCP in
combination with other drugs. The use of alcohol alone is not
reported. The route of administration and form of drug used (e.g.,
powder, tablet, liquid) are included for each drug. Data collected for
DAWN also include drug use motive and total drug mentions in the
episode, as well as race, age, patient disposition, reason for ED
visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.

Database of the nation''s substance abuse and mental health research data providing public use data files, file documentation, and access to restricted-use data files to support a better understanding of this critical area of public health. The goal is to increase the use of the data to most accurately understand and assess substance abuse and mental health problems and the impact of related treatment systems. The data include the U.S. general and special populations, annual series, and designs that produce nationally representative estimates. Some of the data acquired and archived have never before been publicly distributed. Each collection includes survey instruments (when provided), a bibliography of related literature, and related Web site links. All data may be downloaded free of charge in SPSS, SAS, STATA, and ASCII formats and most studies are available for use with the online data analysis system. This system allows users to conduct analyses ranging from cross-tabulation to regression without downloading data or relying on other software. Another feature, Quick Tables, provides the ability to select variables from drop down menus to produce cross-tabulations and graphs that may be customized and cut and pasted into documents. Documentation files, such as codebooks and questionnaires, can be downloaded and viewed online.

The goal of the Arrestee Drug Abuse Monitoring (ADAM) Program is to determine the extent and correlates of illicit drug use in the population of booked arrestees in local areas. Data were collected in 2001 at four separate times (quarterly) during the year in 33 metropolitan areas in the United States. The ADAM program adopted a new instrument in 2000 in adult booking facilities for male (Part 1) and female (Part 2) arrestees. Data from arrestees in juvenile detention facilities (Part 3) continued to use the juvenile instrument from previous years, extending back through the DRUG USE FORECASTING series (ICPSR 9477). The ADAM program in 2001 also continued the use of probability-based sampling for male arrestees in adult facilities, which was initiated in 2000. Therefore, the male adult sample includes weights, generated through post-sampling stratification of the data. For the adult files, variables fell into one of eight categories: (1) demographic data on each arrestee, (2) ADAM facesheet (records-based) data, (3) data on disposition of the case, including accession to a verbal consent script, (4) calendar of admissions to substance abuse and mental health treatment programs, (5) data on alcohol and drug use, abuse, and dependence (6) drug acquisition data covering the five most commonly used illicit drugs, (7) urine test results, and (8) weights. The juvenile file contains demographic variables and arrestee's self-reported past and continued use of 15 drugs, as well as other drug-related behaviors.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.

Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

The Uniform Facility Data Set (UFDS), formerly the National Drug and Alcohol Treatment Unit Survey or NDATUS, was designed to measure the scope and use of drug abuse treatment services in the United States. The survey collects information from each privately- and publicly-funded facility in the country that provides substance abuse treatment as well as from state-identified facilities that provide other substance abuse services. Data are collected on a number of topics including facility operation, services provided (assessment, therapy, testing, health, continuing care, programs for special groups, transitional services, community outreach, ancillary), type of treatment, facility capacity, numbers of clients, and various client characteristics. The main objective of the UFDS is to produce data that can be used to assess the nature and extent of substance abuse treatment services, to assist in the forecast of treatment resource requirements, to analyze treatment service trends, to conduct national, regional, and state-level comparative analyses of treatment services and utilization, and to generate the National Directory of Drug and Alcohol Abuse Treatment Programs and its on-line equivalent, the Substance Abuse Treatment Facility Locator http://findtreatment.samhsa.gov. Additionally, the UFDS provides information that can be used to design sampling frames for other surveys of substance abuse treatment facilities.This study has 1 Data Set.

The Drug Abuse Warning Network (DAWN) survey is designed to
capture data on emergency department (ED) episodes that are induced by
or related to the use of an illicit, prescription, or over-the-counter
drug. For purposes of this collection, a drug "episode" is an ED visit
that was induced by or related to the use of an illegal drug or the
nonmedical use of a legal drug for patients aged six years and
older. A drug "mention" refers to a substance that was mentioned
during a drug-related ED episode. Because up to four drugs can be
reported for each drug abuse episode, there are more mentions than
episodes in the data. Individual persons may also be included more
than once in the data. Within each facility participating in DAWN, a
designated reporter, usually a member of the emergency department or
medical records staff, was responsible for identifying drug-related
episodes and recording and submitting data on each case. An episode
report was submitted for each patient visiting a DAWN emergency
department whose presenting problem(s) was/were related to their own
drug use. DAWN produces estimates of drug-related emergency department
visits for 50 specific drugs, drug categories, or combinations of
drugs, including the following: acetaminophen, alcohol in combination
with other drugs, alprazolam, amitriptyline, amphetamines, aspirin,
cocaine, codeine, diazepam, diphenhydramine, fluoxetine,
heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam,
marijuana/hashish, methadone, methamphetamine, and PCP/PCP in
combination with other drugs. The use of alcohol alone is not
reported. The route of administration and form of drug used (e.g.,
powder, tablet, liquid) are included for each drug. Data collected for
DAWN also include drug use motive and total drug mentions in the
episode, as well as race, age, patient disposition, reason for ED
visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.

The Criminal Justice Drug Abuse Treatment Studies 2 (CJ-DATS 2) was launched in 2008 with a focus on conducting implementation research in criminal justice settings. NIDA's ultimate goal for CJ-DATS 2 was to identify implementation strategies that maximize the likelihood of sustained delivery of evidence-based practices to improve offender drug abuse and HIV outcomes, and to decrease their risk of incarceration. The Medication-Assisted Therapy (MAT) study focuses on implementing linkages to medication assisted treatment in correctional settings. During the study period community corrections staff engaged in training about addiction pharmacotherapies, while leadership in the corrections and treatment facilities engage in a joint strategic planning process to identify and resolve barriers to efficient flow of clients across the two systems. This study includes 28 datasets and over 1,400 variables. The first five datasets for this study contain data on the baseline characteristics of the treatment and corrections sites that participated in the study as well as the characteristics of the staff working at those facilities. Opinions about Medication Assisted Treatment surveys were administered to personnel at the participating corrections and treatment sites (D6). Data on Inter-organization Relations between Probation and Parole staff with Treatment Providers were also collected (DS7-DS18). Information was extracted from the charts of clients about their alcohol and opioid dependence as well as the referrals and treatment the clients received (DS19). Probation and parole officers and treatment providers were surveyed about monthly counts of referrals (DS20-DS21). During the study 10 staff members from the community corrections agency and local treatment providers where MAT services were available were nominated to participate in a Pharmacotherapy Exchange Council (PEC). PEC members were involved with strategic planning for implementing changes to improve the usage of Medication-Assisted Therapy. PEC members were surveyed several times throughout the study. PEC members completed surveys on how well the sites were adhering to the Organizational Linkages Intervention (OLI) process (DS22). Community corrections staff, PEC members and Connections Coordinators in the experimental group were surveyed about their perceptions of organizational benefits and costs associated with the MATICCE intervention (DS23). The PEC rated the Connections Coordinators (DS24)and the Connections Coordinators rate the PEC (DS25). PEC researchers completed surveys on how much of the OLI was completed (DS26) as well as what the sustainability of the changes made through the MATTICE project (DS27). The final dataset provides a key for who took the KPI (Key Performance Indicators) training and who was a PEC member (DS28).

Objectives: Define the role of increasing cannabis availability on population mental health (MH).

Methods. Ecological cohort study of National Survey of Drug Use and Health (NSDUH) geographically-linked substate-shapefiles 2010-2012 and 2014-2016 supplemented by five-year US American Community Survey. Drugs: cigarettes, alcohol abuse, last-month cannabis use and last-year cocaine use. MH: any mental illness, major depressive illness, serious mental illness and suicidal thinking. Data analysis: two-stage and geotemporospatial methods in R.

Results: 410,138 NSDUH respondents. Average response rate 76.7%. When all drug exposure, ethnicity and income variables were combined in final geospatiotemporal models tobacco, alcohol cannabis exposure, and various ethnicities were significantly related to all four major mental health outcomes. Cannabis exposure alone was related to any mental illness (β-estimate= -3.315+0.374, P<2.2x10-16), major depressive episode (β-estimate= -3.712+0.454, P=3.0x10-16), serious mental illness (SMI, β-estimate= -3.063+0.504, P=1.2x10-9), suicidal ideation (β-estimate= -3.013+0.436, P=4.8x10-12) and with more significant interactions in each case (from β-estimate= 1.844+0.277, P=3.0x10-11). Geospatial modelling showed a monotonic upward trajectory of SMI which doubled (3.62% to 7.06%) as cannabis use increased. Extrapolated to whole populations cannabis decriminalization (4.35+0.05%, Prevalence Ratio (PR)=1.035(95%C.I. 1.034-1.036), attributable fraction in the exposed (AFE)=3.28%(3.18-3.37%), P<10-300) and legalization (4.66+0.09%, PR=1.155(1.153-1.158), AFE=12.91% (12.72-13.10%), P<10-300) were associated with increased SMI vs. illegal status (4.26+0.04%).

Conclusions: Data show all four indices of mental ill-health track cannabis exposure and are robust to multivariable adjustment for ethnicity, socioeconomics and other drug use. MH deteriorated with cannabis legalization. Together with similar international reports and numerous mechanistic studies preventative action to reduce cannabis use-exposure is indicated.

This dataset was extracted from the 2019 National Survey on Drug Use and Health, which is an annual survey (starting from 1971) that collects data regarding drug usage and mental health issues in the United States. The survey is run and maintained by the Substance Abuse and Mental Health Services Administration (SAMHSA) –a federal government agency that specializes in behavioral health and research. For more information on the survey (i.e., sampling methods, etc.), please visit this page. The original dataset (as well as datasets from surveys performed in other years) can be retrieved here.

This subset contains 16 categorical features of 56,136 observations, and was originally extracted to be used for a college data analysis project that sought to determine the influence (if any) certain risk factors have on drug usage. The purpose of creating this subset was to simplify moving the dataset around, as well as working with the dataset in general (e.g., less cryptic feature names, etc.) The subset is now offered as is to other students, hobbyists, etc. for practice.

The variables in this data set are substances that survey participants have admitted to using in their past (e.g., cocaine, heroin, meth, etc.), as well as associated risk factors that may influence whether or not an individual engages in drug use (e.g., income bracket, education, sex, etc.). Non-illicit drugs such as alcohol, marijuana*, and pain relief medicine were also of particular interest in the analysis project. Because these substances are often characterized as “gateways” to illicit drug use, it may prove interesting to the analyst to discern how usage of these substances affects the risk of using illicit substances as well.

This repository includes data from the Health Resources & Services Administration's Area Health Resources Files (years 2000, 2004-2019), CDC Wonder, National Conference of State Legislatures, and the Drug Enforcement Agency's Automation of Reports and Consolidated Orders System (ARCOS).

Please cite the following publication when using this dataset:

KN Griffith, Y Feyman, SG Auty, EL Crable, TW Levengood. (in press). County-level data on U.S. opioid distributions, demographics, healthcare supply, and healthcare access, Data in Brief.

These data were originally collected for the following research article:

Griffith, KN, Feyman, Y, Crable, EL, & Levengood, TW. (2021). “Implications of county-level variation in U.S. opioid distribution.” Drug and Alcohol Dependence 219: e108501. https://doi.org/10.1016/j.drugalcdep.2020.108501

The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2012 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.

The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2013 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. This study has 1 Data Set.